{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:59:16Z","timestamp":1790600356490,"version":"4.1.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging breast cancer subtype defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression. Because these classical therapeutic targets are lacking, chemotherapy remains a central systemic treatment; however, TNBC is frequently associated with early recurrence, distant metastasis, immune escape, and therapeutic resistance. Growing evidence shows that these malignant features are strongly shaped by the tumor microenvironment (TME), a complex network of tumor cells, extracellular matrix, stromal cells, immune cells, vascular structures, cytokines, chemokines, and signaling mediators. Compared with hormone receptor-positive breast cancer, TNBC often displays stronger immune infiltration and higher immune-checkpoint activity, suggesting an immune-inflamed phenotype in many cases. Nevertheless, immune-cell presence does not always produce effective antitumor immunity because TNBC can develop PD-L1 upregulation, alternative checkpoint activation, antigen-presentation loss, T-cell exhaustion, macrophage polarization, regulatory T-cell expansion, myeloid-derived suppressor cell recruitment, stromal immune exclusion, hypoxia, metabolic stress, epigenetic regulation, and exosome-mediated immune suppression. This review summarizes TME-driven immune evasion in TNBC, emphasizing molecular heterogeneity, hot and cold immune phenotypes, immunosuppressive cellular networks, PD-1\/PD-L1 signaling, stromal barriers, metastatic immune escape, advances in clinical immunotherapy, adverse effects, and emerging TME-directed strategies. Understanding these mechanisms may support rational combination therapies, biomarker-guided patient selection, and individualized immunotherapeutic approaches for TNBC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1897496","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:13:01Z","timestamp":1790597581000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor microenvironment-driven immune evasion in triple-negative breast cancer: mechanisms, clinical challenges, and therapeutic opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Rheumatology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Breast Thyroid Vascular Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Breast Thyroid Vascular Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danxin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br J Radiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/gco.0000000000000147","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nrclinonc.2011.214","article-title":"Breast cancer.","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"Jama"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz189","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"B10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumors","volume":"490","year":"2012","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/jci45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and management of patients with triple-negative breast cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncologist"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"key":"B23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.cd-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0006-7","article-title":"A history of exploring cancer in context","volume":"18","author":"Maman","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s1470-2045(17)30904-x","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw192","article-title":"Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer","volume":"109","author":"Bense","year":"2017","journal-title":"J Natl Cancer Institute"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-19-0035","article-title":"Risk factors for triple-negative breast cancer among Latina women","volume":"28","author":"Rey-Vargas","year":"2019","journal-title":"Cancer Epidemiology Biomarkers Prev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.600573","article-title":"Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects","volume":"10","author":"Thomas","year":"2021","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cells15090834","article-title":"An update on the role of androgens and androgen receptor in triple-negative breast cancer","volume":"15","author":"Cortes","year":"2026","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8548","article-title":"Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol Lett"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246256","article-title":"Immune milieu and genomic alterations set the triple-negative breast cancer immunomodulatory subtype tumor behavior","volume":"13","author":"Rodr\u00edguez-Bautista","year":"2021","journal-title":"Cancers"},{"key":"B44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/pap.0000000000000232","article-title":"Molecular classification of breast cancer","volume":"27","author":"Tsang","year":"2020","journal-title":"Adv Anatomic Pathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cells15090756","article-title":"Pre-adaptive states and evolutionary trajectories in breast cancer drug resistance: from drug-tolerant persisters to clonal evolution","volume":"15","author":"Choi","year":"2026","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.03.025","article-title":"Mapping intratumor heterogeneity across layers for advancing immunotherapy","volume":"189","author":"Marine","year":"2026","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70403","article-title":"Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Clin Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172938","article-title":"The underlying mechanisms and emerging strategies to overcome resistance in breast cancer","volume":"17","author":"Kannan","year":"2025","journal-title":"Cancers"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1733549","article-title":"Neoantigens in cancer immunoediting: from mechanisms to personalized vaccines in breast cancer","volume":"13","author":"Zeng","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/PPO.0000000000000184","article-title":"From the guest editor: immune checkpoint therapy as a weapon against cancer","volume":"22","author":"Sharma","year":"2016","journal-title":"Cancer J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/jem2093oia1","article-title":"The extracellular matrix: a dynamic niche in cancer progression","volume":"196","author":"Lu","year":"2012","journal-title":"J Cell Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"201","DOI":"10.18502\/ajmb.v16i4.16737","article-title":"Overview on immunopathology of chronic lymphocytic leukemia and tumor-associated antigens with therapeutic applications","volume":"16","author":"Shabani","year":"2024","journal-title":"Avicenna J Med Biotechnol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.02.005","article-title":"Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity","volume":"177","author":"Binnewies","year":"2019","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-026-01650-1","article-title":"Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver","volume":"58","author":"Kim","year":"2026","journal-title":"Exp Mol Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.590941","article-title":"The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy","volume":"10","author":"Ge","year":"2020","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-05-3153","article-title":"Cancer stem cells: an old idea\u2014a paradigm shift","volume":"66","author":"Wicha","year":"2006","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-010-0023-y","article-title":"Emerging strategies for the identification and targeting of cancer stem cells","volume":"31","author":"Dou","year":"2010","journal-title":"Tumor Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0710409","article-title":"Obstacles and opportunities for understanding macrophage polarization","volume":"89","author":"Murray","year":"2011","journal-title":"J Leukocyte Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukocyte Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-10-3323","article-title":"Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion","volume":"71","author":"Dirat","year":"2011","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/intimm\/dxw014","article-title":"Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment","volume":"28","author":"Spranger","year":"2016","journal-title":"Int Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imm.13793","article-title":"Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy","volume":"173","author":"Wang","year":"2024","journal-title":"Immunology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"218350","DOI":"10.1016\/j.canlet.2026.218350","article-title":"Reprogramming the immune microenvironment in triple-negative breast cancer with mrna therapeutics","volume":"645","author":"Verma","year":"2026","journal-title":"Cancer Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18030412","article-title":"Targeting the tumor microenvironment in triple-negative breast cancer: emerging roles of monoclonal antibodies and immune modulation","volume":"18","author":"Figueroa","year":"2026","journal-title":"Cancers"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-3524","article-title":"Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12885-019-5364-3","article-title":"Insluin and epithelial growth factor (EGF) promote programmed death ligand 1 (PD-L1) production and transport in colon cancer stem cells","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159135","article-title":"The evolution of triple-negative breast cancer: from biology to novel therapeutics","volume":"35","author":"Anders","year":"2016","journal-title":"Am Soc Clin Oncol Educ book. Am Soc Clin Oncol Annu Meeting"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/jci80011","article-title":"Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B79","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41419-021-04047-2","article-title":"Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B80","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.7150\/thno.74989","article-title":"UBR5 promotes tumor immune evasion through enhancing IFN-\u03b3-induced PDL1 transcription in triple negative breast cancer","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002115","article-title":"MUC1-C integrates activation of the IFN-\u03b3 pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer","volume":"9","author":"Yamashita","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12935-018-0579-y","article-title":"Interferon-\u03b3 and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNF\u03b1-independent manner","volume":"18","author":"Hao","year":"2018","journal-title":"Cancer Cell Int"},{"key":"B83","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","article-title":"Endoplasmic reticulum stress signals in the tumour and its microenvironment","volume":"21","author":"Chen","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B84","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.15367","article-title":"Endoplasmic reticulum stress\u2010induced exosomal miR\u201027a\u20103p promotes immune escape in breast cancer via regulating PD\u2010L1 expression in macrophages","volume":"24","author":"Yao","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113664","article-title":"Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering","volume":"382","author":"Yang","year":"2025","journal-title":"J Controlled Release"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.119126","article-title":"Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer","volume":"338","author":"Zhou","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16768","article-title":"MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone\u2010mediated autophagy","volume":"290","author":"Zhou","year":"2023","journal-title":"FEBS J"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164139","article-title":"Epigenetic regulation of immunotherapy response in triple-negative breast cancer","volume":"13","author":"Llin\u00e0s-Arias","year":"2021","journal-title":"Cancers"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ccell.2020.12.001","article-title":"Integrin \u03b1v\u03b26\u2013TGF\u03b2\u2013SOX4 pathway drives immune evasion in triple-negative breast cancer","volume":"39","author":"Bagati","year":"2021","journal-title":"Cancer Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","article-title":"FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-013-2922-9","article-title":"Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1","volume":"289","author":"Engel","year":"2014","journal-title":"Arch Gynecology Obstetrics"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2011.10.002","article-title":"Two modes of immune suppression by Foxp3+ regulatory T cells under inflammatory or non-inflammatory conditions","volume":"23","author":"Yamaguchi","year":"2011","journal-title":"Semin Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195278","article-title":"Carcinoma associated fibroblasts (CAFs) promote breast cancer motility by suppressing mammalian Diaphanous-related formin-2 (mDia2)","volume":"13","author":"Dvorak","year":"2018","journal-title":"PloS One"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114298","article-title":"B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy","volume":"183","author":"Cheng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406655111","article-title":"Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment","volume":"111","author":"Chaturvedi","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B105","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.canlet.2021.01.013","article-title":"Targeting FAP\u03b1-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis","volume":"503","author":"Li","year":"2021","journal-title":"Cancer Lett"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02867-x","article-title":"Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis","volume":"70","author":"Tsai","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B107","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.lfs.2019.05.030","article-title":"IL-17A-stimulated endothelial fatty acid \u03b2-oxidation promotes tumor angiogenesis","volume":"229","author":"Wang","year":"2019","journal-title":"Life Sci"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00428","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"10","author":"Sun","year":"2020","journal-title":"Front Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30189","article-title":"Overexpression of GLUT3 promotes metastasis of triple\u2010negative breast cancer by modulating the inflammatory tumor microenvironment","volume":"236","author":"Tsai","year":"2021","journal-title":"J Cell Physiol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202514661","article-title":"Spatial transcriptomics and snRNA\u2010seq expose CAF niches orchestrating dual stromal\u2010immune barriers in hepatocellular carcinoma","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci"},{"key":"B112","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aaf2403","article-title":"Visualization and analysis of gene expression in tissue sections by spatial transcriptomics","volume":"353","author":"St\u00e5hl","year":"2016","journal-title":"Science"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0472-9","article-title":"Multiplex digital spatial profiling of proteins and RNA in fixed tissue","volume":"38","author":"Merritt","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1109\/tcbb.2020.2973148","article-title":"FUNMarker: Fusion network-based method to identify prognostic and heterogeneous breast cancer biomarkers","volume":"18","author":"Li","year":"2020","journal-title":"IEEE\/ACM Trans Comput Biol Bioinf"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40005-025-00731-z","article-title":"Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy","volume":"55","author":"Yuan","year":"2025","journal-title":"J Pharm Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11010146","article-title":"Cancer vaccines for triple-negative breast cancer: a systematic review","volume":"11","author":"Hosseini","year":"2023","journal-title":"Vaccines"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-20-0385","article-title":"Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer","volume":"19","author":"Dees","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B126","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062795","article-title":"Tumor microenvironment dynamics of triple-negative breast cancer under radiation therapy","volume":"26","author":"Niture","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/electronics14214247","article-title":"Breast ultrasound image detection based on dual-branch Faster R-CNN","volume":"14","author":"Liu","year":"2025","journal-title":"Electronics"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1689103","article-title":"Identification and validation of prognostic genes and prognostic models associated with cutaneous melanoma and integrative stress response","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/cells14171353","article-title":"The role of tumor microenvironment in triple-negative breast cancer and its therapeutic targeting","volume":"14","author":"Vuleti\u0107","year":"2025","journal-title":"Cells"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1630464","article-title":"Immunotherapy resistance in triple-negative breast cancer: Molecular mechanisms, tumor microenvironment, and therapeutic implications","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nri.2017.76","article-title":"Single-cell RNA sequencing to explore immune cell heterogeneity","volume":"18","author":"Papalexi","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"20170387","DOI":"10.1098\/rsif.2017.0387","article-title":"Opportunities and obstacles for deep learning in biology and medicine","volume":"15","author":"Ching","year":"2018","journal-title":"J R Soc Interface"},{"key":"B134","doi-asserted-by":"publisher","first-page":"0247","DOI":"10.34133\/cbsystems.0247","article-title":"Hollow mesoporou carbon nanosphere derived from MOF for sono-immunotherapy against pancreatic cancer","volume":"6","author":"Chen","year":"2025","journal-title":"Cyborg Bionic Syst"},{"key":"B135","doi-asserted-by":"publisher","first-page":"109559","DOI":"10.1016\/j.mbs.2025.109559","article-title":"Analyzing the impact of threshold strategies on cancer treatment using non-smooth models","volume":"390","author":"Wu","year":"2025","journal-title":"Math Biosci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1897496\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:13:04Z","timestamp":1790597584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1897496\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2026.1897496"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1897496","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1897496"}}